GAMIDA CELL LTD (GMDA) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:GMDA • IL0011552663

0.0327 USD
-0.01 (-18.25%)
At close: Apr 5, 2024
0.032 USD
0 (-2.14%)
After Hours: 4/5/2024, 8:00:00 PM

GMDA Key Statistics, Chart & Performance

Key Statistics
Market Cap4.34M
Revenue(TTM)1.78M
Net Income(TTM)-63.00M
Shares132.64M
Float117.28M
52 Week High2.51
52 Week Low0.03
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.63
PEN/A
Fwd PEN/A
Earnings (Next)05-07
IPO2018-10-26
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
GMDA short term performance overview.The bars show the price performance of GMDA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

GMDA long term performance overview.The bars show the price performance of GMDA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of GMDA is 0.0327 USD. In the past month the price decreased by -90.3%. In the past year, price decreased by -95.57%.

GAMIDA CELL LTD / GMDA Daily stock chart

GMDA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

GMDA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to GMDA. Both the profitability and financial health of GMDA have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GMDA Financial Highlights

Over the last trailing twelve months GMDA reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 49.19% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -61.65%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%86.67%
Sales Q2Q%N/A
EPS 1Y (TTM)49.19%
Revenue 1Y (TTM)N/A

GMDA Forecast & Estimates

10 analysts have analysed GMDA and the average price target is 4.42 USD. This implies a price increase of 13416.73% is expected in the next year compared to the current price of 0.0327.

For the next year, analysts expect an EPS growth of 9.37% and a revenue growth 808.75% for GMDA


Analysts
Analysts80
Price Target4.42 (13416.82%)
EPS Next Y9.37%
Revenue Next Year808.75%

GMDA Ownership

Ownership
Inst Owners0.24%
Ins Owners3.15%
Short Float %N/A
Short RatioN/A

GMDA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.3387.092B
AMGN AMGEN INC16.64198.053B
GILD GILEAD SCIENCES INC16.79185.32B
VRTX VERTEX PHARMACEUTICALS INC22.93116.409B
REGN REGENERON PHARMACEUTICALS16.5480.573B
ALNY ALNYLAM PHARMACEUTICALS INC46.8243.76B
INSM INSMED INC N/A32.21B
NTRA NATERA INC N/A27.199B
BIIB BIOGEN INC12.4827.192B
UTHR UNITED THERAPEUTICS CORP16.4720.623B

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges

About GMDA

Company Profile

GMDA logo image Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The firm is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Company Info

GAMIDA CELL LTD

PO Box 34670

JERUSALEM 95484 IL

CEO: Julian Adams

Employees: 143

GMDA Company Website

Phone: 97226595666

GAMIDA CELL LTD / GMDA FAQ

Can you describe the business of GAMIDA CELL LTD?

Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The firm is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.


Can you provide the latest stock price for GAMIDA CELL LTD?

The current stock price of GMDA is 0.0327 USD. The price decreased by -18.25% in the last trading session.


What is the dividend status of GAMIDA CELL LTD?

GMDA does not pay a dividend.


What is the ChartMill rating of GAMIDA CELL LTD stock?

GMDA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the expected growth for GMDA stock?

The Revenue of GAMIDA CELL LTD (GMDA) is expected to grow by 808.75% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is the employee count for GMDA stock?

GAMIDA CELL LTD (GMDA) currently has 143 employees.